/

LGND

Ligand Pharmaceuticals IncorporOpen

307.03−4.11 −1.32%USD

NasdaqGM · as of Oct 13, 10:17 ET · 15m delay

Open

311.72

Prev close

311.13

Day range

305.19311.72

52-week range

175.89326.63

Volume

19.50K0.08×

Mkt cap

6.12B

P/E ttm

32.35

Fwd P/E

25.69

EPS ttm

9.49

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−6.00%

Price Chart

Yahoo Finance · delayed

LGNDOct 13, 2026O 311.72H 311.72L 305.19C 307.02−4.11 (−1.32%)Vol 19.50K

SMA 50292.81
SMA 200245.42

1Y change +72.75% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

LGND Ligand Pharmaceuticals Incorpor · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +3.40%
1 month: +7.93%
3 months: +2.01%
6 months: +32.14%
Year to date: +62.39%
1 year: +70.67%

Valuation & ownership

Market cap: 6.12B
Enterprise value: 5.98B
P/E (ttm): 32.35
Forward P/E: 25.69
PEG ratio: 1.53
Price / book: 6.32
Price / sales (ttm): 21.07
EV / EBITDA: 44.93
EPS (ttm): 9.49
EPS (forward): 11.95
Beta (5y monthly): 1.01
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 19.94M
Float: 19.49M
Short % of float: 16.11%
Short ratio (days): 10.56
Held by insiders: 2.32%
Held by institutions: 116.11%
Avg volume (3m): 258.00K
50-day average: 292.51
200-day average: 244.87
52-week change: +70.67%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 57.3
vs 50-day SMA: +4.85%
vs 200-day SMA: +25.10%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.27%
Realised vol (20d, ann.): 32.5%
From 52-week high: −6.00%
From 52-week low: +74.56%

ANR

Analyst Consensus

12 analysts

Consensus

—

Mean target

344.25

+12.12% implied

Low 247.00Median 345.00High 397.00

Recommendation trend

Now11 / 0 / 0
1m ago10 / 0 / 0

DES

About Ligand Pharmaceuticals Incorpor

Yahoo Finance profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 47
Headquarters: Jupiter, FL, United States
Website: ligand.com

SEAS

Seasonality · LGND

2007–2026 · monthly returns

Strongest month Jun +5.83%Weakest month Sep −2.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	1.6	3.2	0.7	14.9	1.1	36.3	-9.0	-1.2	10.0	-1.7			+62.4%
2025	8.8	4.9	-14.0	4.5	-7.0	11.2	15.7	22.9	9.5	8.0	6.2	-6.9	+76.5%
2024	2.4	8.5	-7.9	-4.4	21.7	-0.9	29.3	-2.9	-5.4	5.6	14.9	-11.8	+50.0%
2023	4.3	3.5	2.0	3.8	-8.2	2.9	-7.2	-1.7	-8.9	-12.7	11.5	22.5	+6.9%
2022	-19.3	-18.8	11.1	-17.5	-4.3	0.3	3.1	0.4	-6.8	1.8	33.3	-8.4	−30.7%
2021	86.4	-20.0	2.9	-4.3	-19.3	11.5	-13.5	16.6	5.3	4.8	10.9	-4.6	+55.3%
2020	-15.8	6.6	-22.3	35.5	3.0	10.1	4.8	-13.0	-6.5	-13.5	2.3	17.9	−4.6%
2019	-13.0	5.1	1.3	0.1	-14.7	6.3	-19.8	-0.7	9.5	9.3	3.9	-7.7	−23.1%
2018	15.1	-3.6	8.7	-6.2	24.1	7.8	5.4	18.9	5.7	-40.0	-4.3	-14.0	−0.9%
2017	4.3	-1.3	1.2	5.0	-2.6	12.1	-0.4	6.6	5.6	6.8	-9.3	3.9	+34.8%
2016	-7.8	-7.7	16.0	12.9	-1.1	-0.3	13.1	-23.4	-1.2	-6.2	9.1	-2.7	−6.3%
2015	7.0	-3.3	40.0	0.7	13.5	14.5	7.3	-15.1	-6.8	5.5	18.5	1.3	+103.8%
2014	17.8	12.6	-3.6	-6.1	5.6	-6.6	-21.1	5.8	-9.7	17.6	-2.6	-1.2	+1.2%
2013	-3.1	2.2	29.7	2.5	9.5	25.0	26.7	1.5	-10.0	19.6	7.6	-5.5	+153.6%
2012	4.8	18.0	8.7	-15.3	-7.3	35.2	14.2	-10.6	-0.8	-10.1	28.0	5.1	+74.7%
2011	-2.5	24.6	-7.7	11.1	-4.6	12.7	14.0	11.8	-10.2	7.5	-20.2	1.2	+33.1%
2010	-18.4	-0.6	-1.1	5.7	-16.3	-5.2	13.0	-12.1	9.0	2.5	-13.2	5.7	−31.5%
2009	-22.6	27.8	10.0	0.3	-0.3	-4.0	-1.0	-15.2	-3.8	-26.4	16.5	9.6	−20.8%
2008	-13.9	-18.5	18.0	1.2	-13.3	-25.9	28.1	1.5	-12.7	-29.8	-0.5	33.0	−43.3%
2007	18.6	-13.5	-10.3	-32.4	-2.9	4.1	-21.5	16.1	-14.8	0.7	-8.7	-1.6	−55.9%

INSD

Insider Activity · LGND

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

73.9K shares

Sells, 6 months

90.7K shares

Net shares

−16.8K

Net change in insider shares

−3.50%

Date	Insider	Transaction	Shares	Value
Oct 1, 2026	Reardon Andrew ThomasOfficer	Sale at price 302.51 - 307.74 per share.	5K	$1.52M
Oct 1, 2026	Reardon Andrew ThomasOfficer	Conversion of Exercise of derivative security at price 52.27 per share.	340	$17.77K
Sep 9, 2026	Zimmermann MartineDirector	Sale at price 285.00 per share.	1.2K	$342.00K
Sep 2, 2026	Reardon Andrew ThomasOfficer	Sale at price 283.99 - 288.98 per share.	5K	$1.43M
Aug 11, 2026	Haas JasonDirector	Sale at price 292.81 per share.	7.1K	$2.09M
Aug 11, 2026	Haas JasonDirector	Conversion of Exercise of derivative security at price 51.56 per share.	6.1K	$316.48K
Aug 11, 2026	Espinoza OctavioChief Financial Officer	Sale at price 292.06 per share.	31.6K	$9.24M
Aug 11, 2026	Espinoza OctavioChief Financial Officer	Conversion of Exercise of derivative security at price 52.84 - 70.04 per share.	31.6K	$1.80M
Aug 2, 2026	Reardon Andrew ThomasOfficer	Sale at price 284.14 - 292.82 per share.	5K	$1.44M
Aug 2, 2026	Reardon Andrew ThomasOfficer	Conversion of Exercise of derivative security at price 52.27 per share.	5K	$261.35K
Jun 30, 2026	Reardon Andrew ThomasOfficer	Sale at price 308.99 - 317.15 per share.	5K	$1.57M
Jun 30, 2026	Reardon Andrew ThomasOfficer	Conversion of Exercise of derivative security at price 52.27 per share.	5K	$261.35K
Jun 15, 2026	Sabba Stephen L.Director	Sale at price 254.00 per share.	2.1K	$544.83K
Jun 15, 2026	Sabba Stephen L.Director	Conversion of Exercise of derivative security at price 66.13 per share.	2.1K	$141.85K
Jun 11, 2026	Haas JasonDirector	Sale at price 255.01 - 256.08 per share.	6.5K	$1.65M
Jun 11, 2026	Haas JasonDirector	Conversion of Exercise of derivative security at price 51.56 per share.	4K	$206.24K
Jun 10, 2026	Aryeh Jason MDirector	Sale at price 250.00 per share.	5K	$1.25M
Jun 9, 2026	Lamattina John LDirector	Sale at price 247.22 - 251.62 per share.	4.6K	$1.15M
Jun 4, 2026	Kozarich John W.Director	Stock Award(Grant) at price 0.00 per share.	836	—
Jun 4, 2026	Lamattina John LDirector	Stock Award(Grant) at price 0.00 per share.	836	—

CONG

Congress Trades · LGND

House and Senate reports since 2025

Members

1 last bought

Buys

~$32.0K

Sells

~$0

Net

+$32.0K

est. bought − sold

Latest

May 29, 26

Gilbert Cisneros

Members who traded it

Member	Buys	Sells	Est. net	Last move
Gilbert Cisneros CA31	4		+$32.0K	Bought May 29, 26

Bought and sold by quarter (est.)

Members of Congress's LGND trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
May 29, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Jun 8, 26 (10d)	PDF
Mar 3, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Apr 7, 26 (35d)	PDF
Jan 15, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Feb 13, 26 (29d)	PDF
Jan 5, 26	Gilbert Cisneros CA31	Self	Buy	$1,001 - $15,000	Feb 13, 26 (39d)	PDF

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

LGND

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

LGND

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ligand Pharmaceuticals Incorpor

Seasonality · LGND

Insider Activity · LGND

Congress Trades · LGND

Members who traded it

Bought and sold by quarter (est.)

Investors Holding LGND

Investors Holding LGND

Congress Trades · LGND

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · LGND

Seasonality · LGND

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Ligand Pharmaceuticals Incorpor

Financial Snapshot

Earnings & Dividends

News